Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung

D. H. Johnson, P. J. Marangos, J. T. Forbes, J. D. Hainsworth, R. Van Welch, K. R. Hande, F. A. Greco

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

To assess the value of neuron-specific enolase (NSE) as a possible biomarker of small cell lung cancer, serum levels were determined by radioimmunoassay in 93 newly diagnosed untreated patients and were compared to the NSE levels of 20 healthy adult controls [9.6 ± 0.7 (S.E.) ng/ml]. Serum NSE was elevated (>20 ng/ml) in 73% of all patients including 23 of 39 (59%) with limited-stage disease and 45 of 54 (83%) with extensive-stage disease. The mean serum NSE was significantly higher in extensive-stage disease (94.5 ± 13.8 ng/ml) compared to the mean value for limited-stage disease (33.7 ± 4.7 ng/ml) (p < 0.001). NSE was elevated in all patients with 3 or more sites of metastatic disease. Serial NSE determinations were obtained on 57 small cell lung cancer patients. NSE levels fell in 40 of 50 (80%) of patients responding to treatment, increased in 5 of 7 (71%) of patients with progressive disease, and increased in 30 of 35 (86%) of patients who relapsed. A persistent rise in serum NSE occurred as many as 12 weeks before the clinical recognition of relapse in 15 of 23 (65%) of patients for whom adequate serial NSE data were available. These findings indicate that serum NSE may be a useful marker for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)5409-5414
Number of pages6
JournalCancer Research
Volume44
Issue number11
StatePublished - 1984

Fingerprint

Phosphopyruvate Hydratase
Small Cell Lung Carcinoma
Serum
Recurrence
Radioimmunoassay
Biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnson, D. H., Marangos, P. J., Forbes, J. T., Hainsworth, J. D., Van Welch, R., Hande, K. R., & Greco, F. A. (1984). Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Research, 44(11), 5409-5414.

Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. / Johnson, D. H.; Marangos, P. J.; Forbes, J. T.; Hainsworth, J. D.; Van Welch, R.; Hande, K. R.; Greco, F. A.

In: Cancer Research, Vol. 44, No. 11, 1984, p. 5409-5414.

Research output: Contribution to journalArticle

Johnson, DH, Marangos, PJ, Forbes, JT, Hainsworth, JD, Van Welch, R, Hande, KR & Greco, FA 1984, 'Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung', Cancer Research, vol. 44, no. 11, pp. 5409-5414.
Johnson DH, Marangos PJ, Forbes JT, Hainsworth JD, Van Welch R, Hande KR et al. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Research. 1984;44(11):5409-5414.
Johnson, D. H. ; Marangos, P. J. ; Forbes, J. T. ; Hainsworth, J. D. ; Van Welch, R. ; Hande, K. R. ; Greco, F. A. / Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. In: Cancer Research. 1984 ; Vol. 44, No. 11. pp. 5409-5414.
@article{0ed53655af2d423c98f755074cea54c3,
title = "Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung",
abstract = "To assess the value of neuron-specific enolase (NSE) as a possible biomarker of small cell lung cancer, serum levels were determined by radioimmunoassay in 93 newly diagnosed untreated patients and were compared to the NSE levels of 20 healthy adult controls [9.6 ± 0.7 (S.E.) ng/ml]. Serum NSE was elevated (>20 ng/ml) in 73{\%} of all patients including 23 of 39 (59{\%}) with limited-stage disease and 45 of 54 (83{\%}) with extensive-stage disease. The mean serum NSE was significantly higher in extensive-stage disease (94.5 ± 13.8 ng/ml) compared to the mean value for limited-stage disease (33.7 ± 4.7 ng/ml) (p < 0.001). NSE was elevated in all patients with 3 or more sites of metastatic disease. Serial NSE determinations were obtained on 57 small cell lung cancer patients. NSE levels fell in 40 of 50 (80{\%}) of patients responding to treatment, increased in 5 of 7 (71{\%}) of patients with progressive disease, and increased in 30 of 35 (86{\%}) of patients who relapsed. A persistent rise in serum NSE occurred as many as 12 weeks before the clinical recognition of relapse in 15 of 23 (65{\%}) of patients for whom adequate serial NSE data were available. These findings indicate that serum NSE may be a useful marker for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer.",
author = "Johnson, {D. H.} and Marangos, {P. J.} and Forbes, {J. T.} and Hainsworth, {J. D.} and {Van Welch}, R. and Hande, {K. R.} and Greco, {F. A.}",
year = "1984",
language = "English (US)",
volume = "44",
pages = "5409--5414",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung

AU - Johnson, D. H.

AU - Marangos, P. J.

AU - Forbes, J. T.

AU - Hainsworth, J. D.

AU - Van Welch, R.

AU - Hande, K. R.

AU - Greco, F. A.

PY - 1984

Y1 - 1984

N2 - To assess the value of neuron-specific enolase (NSE) as a possible biomarker of small cell lung cancer, serum levels were determined by radioimmunoassay in 93 newly diagnosed untreated patients and were compared to the NSE levels of 20 healthy adult controls [9.6 ± 0.7 (S.E.) ng/ml]. Serum NSE was elevated (>20 ng/ml) in 73% of all patients including 23 of 39 (59%) with limited-stage disease and 45 of 54 (83%) with extensive-stage disease. The mean serum NSE was significantly higher in extensive-stage disease (94.5 ± 13.8 ng/ml) compared to the mean value for limited-stage disease (33.7 ± 4.7 ng/ml) (p < 0.001). NSE was elevated in all patients with 3 or more sites of metastatic disease. Serial NSE determinations were obtained on 57 small cell lung cancer patients. NSE levels fell in 40 of 50 (80%) of patients responding to treatment, increased in 5 of 7 (71%) of patients with progressive disease, and increased in 30 of 35 (86%) of patients who relapsed. A persistent rise in serum NSE occurred as many as 12 weeks before the clinical recognition of relapse in 15 of 23 (65%) of patients for whom adequate serial NSE data were available. These findings indicate that serum NSE may be a useful marker for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer.

AB - To assess the value of neuron-specific enolase (NSE) as a possible biomarker of small cell lung cancer, serum levels were determined by radioimmunoassay in 93 newly diagnosed untreated patients and were compared to the NSE levels of 20 healthy adult controls [9.6 ± 0.7 (S.E.) ng/ml]. Serum NSE was elevated (>20 ng/ml) in 73% of all patients including 23 of 39 (59%) with limited-stage disease and 45 of 54 (83%) with extensive-stage disease. The mean serum NSE was significantly higher in extensive-stage disease (94.5 ± 13.8 ng/ml) compared to the mean value for limited-stage disease (33.7 ± 4.7 ng/ml) (p < 0.001). NSE was elevated in all patients with 3 or more sites of metastatic disease. Serial NSE determinations were obtained on 57 small cell lung cancer patients. NSE levels fell in 40 of 50 (80%) of patients responding to treatment, increased in 5 of 7 (71%) of patients with progressive disease, and increased in 30 of 35 (86%) of patients who relapsed. A persistent rise in serum NSE occurred as many as 12 weeks before the clinical recognition of relapse in 15 of 23 (65%) of patients for whom adequate serial NSE data were available. These findings indicate that serum NSE may be a useful marker for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021750946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021750946&partnerID=8YFLogxK

M3 - Article

C2 - 6091878

AN - SCOPUS:0021750946

VL - 44

SP - 5409

EP - 5414

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -